Retatrutide appears to be a new treatment in the fight against obesity. This novel drug, classified as a dual GLP-1 and GIP receptor agonist, demonstrates promising results in investigations. By stimulating these receptors, Retatrutide controls cravings, {promotesinsulin secretion, and ultimately contributes to significant slimming. While research